|
See related Fabrazyme inj[法布瑞酶凍晶注射劑] information |
|
|
|
製造商 |
Genzyme |
|
代理/經銷商 |
TSPC |
|
成份 |
Agalsidase β |
|
適應症 |
Fabry disease. |
|
用量 |
1 mg/kg body weight every 2 weeks as IV infusion. |
|
過量 |
View Fabrazyme[法布瑞酶] overdosage for action to be taken in the event of an overdose. |
|
美國食品藥物管理局之懷孕等級 |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
禁忌 |
[Click for Fabrazyme[法布瑞酶] detailed prescribing infomation] |
|
警告 |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Fabrazyme[法布瑞酶] detailed prescribing infomation |
|
注意事項 |
Patients should receive antipyretics prior to infusion. Compromised cardiac function. Pregnancy, lactation. Children < 8 years. |
|
不良反應 |
Infusion reactions, stroke, pain, ataxia, bradycardia, cardiac arrhythmia, cardiac arrest, decreased cardiac output, vertigo, hypoacousia, and nephrotic syndrome.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
[Click for Fabrazyme[法布瑞酶] detailed prescribing infomation]
View more drug interactions with Fabrazyme[法布瑞酶] |
|
使用上注意 |
For caution against possible variation of physical aspect of medicine... click to view Fabrazyme[法布瑞酶] detailed prescribing infomation |
|
儲存 |
View Fabrazyme[法布瑞酶] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Fabrazyme[法布瑞酶] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Fabrazyme[法布瑞酶] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
|
|
Manufacturer: |
Genzyme |
|
Distributor: |
TSPC |
|
|
|
|
|
